Monitoring SARS-CoV-2 genetic variability: A post-market surveillance workflow for combined bioinformatic and laboratory evaluation of commercial RT-PCR assay performance.

Barbara Kosińska-SelbiJustyna KowalczykJagoda PierścińskaJarosław WełeszczukLuis PeñarrubiaBenjamin TurnerJosep ParejaRoberto PorcoRubi Diaz-HernandezMartí Juanola-FalgaronaMelisa ReyDavide ManisseroAnna Blacha

Published in: PloS one (2024)

The current study demonstrates that SARS-CoV-2 genetic variants do not affect the performance of the QIAstat-Dx device. It is recommended that manufacturers incorporate this workflow into obligatory post-marketing surveillance activities, as this approach could potentially enhance genetic monitoring of their product.

Keyphrases

sars cov
public health
respiratory syndrome coronavirus
genome wide
electronic health record
copy number
high throughput
health insurance
dna methylation
coronavirus disease